Factors Influencing HPV Vaccine Use among Racially Diverse Female College Students by Cohen, Timmerie F & Legg, Jeffrey
75 Factors Influencing HPV Vaccine Use among Racially Diverse Female College Students -Timmerie 
Cohen et al. 
 
Journal of Health Disparities Research and Practice Volume 8, Issue 2 Summer 2015 
 http://digitalscholarship.unlv.edu/jhdrp/ 
Journal of Health Disparities Research and Practice 
Volume 8, Issue 2, Summer 2015, pp. 75-88 
© 2011 Center for Health Disparities Research 
School of Community Health Sciences 
University of Nevada, Las Vegas 
 
 
Factors Influencing HPV Vaccine Use among Racially Diverse Female College 
Students 
 
Timmerie Cohen, Virginia Commonwealth University 
Jeffrey S. Legg, Virginia Commonwealth University 
Janet Hutchinson, Virginia Commonwealth University 
Jason Levy, Virginia Commonwealth University 
William Bosher, Virginia Commonwealth University 
 
ABSTRACT 
Objective: This study describes Human Papillomavirus (HPV) vaccination rates and possible 
factors influencing vaccination utilization rates in a diverse population of college women 18-
26 years old.   
Methods: The National College Health Assessment survey provided a large diverse sample 
size (N=67,762) in which to perform descriptive and binary logistic regression analysis.  
Demographic characteristics were analyzed as potential barriers to HPV vaccination.  
Additionally, lack of certain health behaviors were explored as potential barriers to HPV 
vaccination.   
Results: In this study, White/non-Hispanic women had a higher HPV vaccination rate when 
compared to minority women. Binary regression analysis demonstrated that minority women 
were less likely to receive the HPV vaccine.  Women who received a gynecological exam 
were more likely to receive the vaccine, as were women who had health insurance coverage.  
Health indicators predictive of receiving the HPV vaccine included receiving the influenza 
vaccine and not reporting obesity.  Furthermore, as the age of the respondents increased, the 
likelihood of receiving the vaccine decreased.   Similarly as the number of reported sexual 
partners increased the likelihood of receiving the HPV vaccine increased.   
Conclusion:  Advocacy for increased provider visits (i.e., gynecological exams) and other 
preventive health services (such as influenza vaccine drives) in the female student population 
could be an opportunity for increased HPV education and vaccination.  Realization that 
minority women in higher education may have lower HPV vaccination rates may be a 
catalyst for student health departments to explore health promotion activities to benefit these 
women.   
 
Keywords: Human Papillomavirus; vaccination; college women; health disparities; health 
promotion; Patient Protection and Affordable Care Act (2010) 
 
INTRODUCTION 
Human Papillomavirus (HPV) is the most prevalent sexually transmitted disease in the 
U.S. This virus causes genital warts and 98% of cervical cancers in women. According to the 
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Centers for Disease Control and Prevention (CDC) 50% of the reproductive-age population in 
the US has been infected with HPV.  Both women and men between 20-24 years are at the 
greatest risk of infection.  The average onset of cervical cancer is 45-55 years. It is important to 
note that HPV is also linked to vaginal, vulvar, anal and oropharyngeal cancers (Centers for 
Disease Control and Prevention, HPV fact sheet, 2010).  Black, Hispanic, and Native American 
women are at an increased risk for developing cervical cancer compared to White women 
(Centers for Disease Control and Prevention, 2012).  Unfortunately, being a member of an ethic 
minority has been linked to decreased cervical cancer screening (McAlearney, Song, Rhoda, 
Tatum, Lemeshow, & Ruffin 2010, Swan, Coates, Rimer, & Lee, 2003, Solomon, Breen, & 
McNeel, 2007).   
In 2006 the Food and Drug Administration (FDA) endorsed a vaccine that offers 
protection against the high risk HPV subtypes 16 and 18.   The FDA approved the vaccine for 
women ages 9-26 and it was also deemed safe for males.  Despite FDA endorsement and CDC 
recommendations, the CDC reported in 2012 that only 54% of girls under the age of 18 received 
the HPV vaccine.  The American Public Health Association (2009) reported that only 41% of 
female undergraduate students surveyed were vaccinated against HPV.  Healthy People 2020 
calls for an HPV vaccination rate of 80% in women.  Achieving the Healthy People 2020 
vaccination target will require an understanding of current HPV vaccination patterns and 
barriers.  
The current targeted population for HPV vaccination is adolescent girls between the ages 
of 11-13 years since the greatest benefit of the vaccine is realized before their first sexual 
encounter (Markowitz, 2007).  This vaccine has the potential to decrease disease burden from 
cervical cancer in women between the ages of 18-26 as well.  Vaccination in women up to the 
age of 26 years is supported by the CDC when there is no prior exposure to the virus, the virus is 
transient or when the vaccine can provide protection from non-present HPV strains (Elbasha & 
Galvani, 2005).  It is important to note that this virus is not predictable after exposure.  The 
natural history of HPV infection has proved difficult to predict due to the virus’ transient nature, 
many infections clear the body within two years with no ill effects to the carrier (Adams, Jasani, 
& Fiander, 2009, Castellsague, Munoz, Pitisuttithum, Ferris, Monsoego, & Ault, 2011, Goldie, 
Grima, Kohli, Wright, Weinstein, & Franco, 2003, Harper, Franco, Wheeler, Ferris, Jenkins & 
Schuind 2004, Schiffman, Castle, Jeronimo, Rodriquez & Wacholder, 2007).   Considering that 
high risk strains of the HPV virus that do not clear the body have the potential to cause cancer, 
exploring avenues to increase vaccination may be warranted.  
The CDC defines the HPV vaccination catch-up group as women ages 18-26 years who 
may not be aware of the 2006 vaccine recommendations and/or did not receive the HPV vaccine. 
Women in the catch-up group could potentially suffer disproportionately from HPV related 
diseases when compared to their younger counterparts.  The public health standpoint is that 
vaccinations are used to reduce harm to individuals, the HPV vaccine does that by protecting 
against a common virus therefore its promotion should be studied (Belong, 2009, Zimmerman, 
2006).  Acknowledging possible barriers to HPV vaccination has the potential to inform health 
promoters in designing multiple strategies that fit specific populations within college 
populations.   
Potential Barriers to HPV Vaccination 
Potential barriers to HPV vaccination include but are not limited to race, age, 
socioeconomic factors, absence of knowledge and lack of preventive health behaviors such as 
provider recommendation and health insurance. Race has been linked to lower HPV vaccination 
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rates in the Black, Hispanic, and Asian college women when compared to White women 
(Bendik, Mayo, and Parker, 2011, Licht, Murphy, Hyland, Fix, Hawk, Mahoney, 2010).  
Conversely some research has found that race was not predictive of HPV vaccination (Brewer & 
Fazekas, 2007, Caskey, Lindau, & Alexander, 2009).  Existing studies regarding HPV 
vaccination in college women are limited and the studies that have been conducted have small 
homogenous sample sizes (Caron, Kispert, & McGrath, 2009, Caskey, et al., 2009, Kahn, 
Rosenthal, Yan, Bin, Namakydoust, & Zimet, 2008, Licht, et al., 2010, Marchand, Glenn, & 
Bastani, 2012, Bandik, et al., 2011, Caskey, et al., 2009, Marchand, et al., 2012).   Increasing 
research using larger, diverse sample sizes has the potential to be more representative of the 
female college population.  
When exploring whether or not age was a barrier to HPV vaccination, it was not 
surprising that 18 year olds were more likely to be exposed to the 2006 vaccination 
recommendation when compared to their 26 year old counterparts (Licht, et al, 2010).  Increased 
research following HPV vaccination trends will reveal if vaccination rates reach equity across 
age groups as time progresses.  Research has also shown that health care providers have the 
opportunity to impact HPV vaccination rates.  Studies have revealed that provider 
recommendation increases the likelihood that women will seek the HPV vaccine (Bendik, et al., 
2011, Brewer & Fazekas, 2007, Giambi, Donati, Declich, Salmaso, Degli, Marta, & Alibrandi, 
2011, Rosenthal, Weiss, & Zimet, 2011). Similarly vaccine acceptability was higher when 
individuals believed that their physician would recommend it (Brewer, et al., 2007).  One 
interesting study of professional women found that 71.6% of respondents reported that their 
physicians did not discuss HPV with them (Cermak, Cottrell, &, Murnan, 2010).  Keane, Walter, 
Patel, Moorthy, Stevens, and Bradley (2005) cited that doctors and nurses are sources of credible 
information regarding vaccination. Again, this gives them the opportunity to influence 
vaccination rates. Marchand and colleagues (2012) emphasized the need for increased provider 
to patient education to increase HPV vaccination rates in college age women.  It is important to 
acknowledge that physicians themselves may face barriers such as safety concerns, efficacy 
concerns, and inadequate reimbursements when recommending the HPV vaccine (Young, 
Bernheim, Korte, Stoler, Guterbock, & Rice, 2011). Increasing provider recommendation needs 
continued research to further promote the HPV vaccine.    
At first glance, one would assume that a vaccine that prevents cancer would be widely 
endorsed by physicians and sought after by patients. However, there is a stigma surrounding this 
vaccine. Public health policymakers have encountered determined resistance to the vaccine from 
some parents, either because of general concerns about vaccine safety or specific objections to 
the vaccine because of its perceived connection with sexual activity. One concern is “that 
vaccination against a sexually transmitted disease would increase sexual activity in young girls 
and unmarried women.” There is no data to support this assertion (Colgrove, 2006, National 
Conference of State Legislatures, 2012).   While assessing the stigma of the HPV vaccination 
would be cumbersome, it should be a focus of future research to advance sexual health 
promotion.     
 Additional barriers to vaccination include general health, socioeconomic status and health 
knowledge. A 2000 study using the National Health Interview Survey found that women who 
reported themselves to be obese were less likely to receive Pap smears.  Obese women were also 
found to have a higher mortality rate due to cervical cancer (Wee, McCarthy, Davis, & Phillips, 
2000).  Exploring obesity as a barrier to preventive care is justifiable for all groups of women. 
Lower socioeconomic status and the lack of health insurance are also associated with decreased 
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rates of cervical cancer screening (Kessels, Marshall, Watson, Brauncak-Mayer, Reuzel, & 
Tooher, 2012).  Conversely, higher uptake of HPV vaccination has been associated with having 
health insurance (Kessels, et al, 2012).  Additional research comparing health status and HPV 
vaccination patterns is warranted.   
Lack of knowledge about HPV and its association with various cancers is a barrier to 
vaccination (Brewer & Fazekas, 2007, Giambi, et al., 2011, Rosenthal, et al, 2011).  Bendik and 
colleagues (2011) demonstrated that 80% of college women did not believe that they were at risk 
for HPV, when in fact they were.  Increased education regarding the HPV virus could prove to 
be an opportunity to increase vaccination rates. Student health is a source of sexual health care 
for college women and therefore, a potential source of information regarding HPV vaccination. 
The President’s Cancer Panel (2012) has made increasing HPV vaccination rates a 
national priority (National Cancer Institute, The President’s Cancer Panel, 2012). In addition, the 
Affordable Care Act (2010) aims to increase preventive care, which makes research regarding 
barriers to vaccination essential.  In order to increase HPV vaccination rates, a greater 
understanding of barriers faced by women needs to be explored.  This research uses a large 
diverse sample gathered from numerous U.S. institutions of higher education to better understand 




The National College Health Assessment (NCHA), administered by the American 
College Health Association (ACHA), was used.  ACHA is a non-profit organization providing 
advocacy to student health organizations.  The NCHA survey has been utilized by 587 
colleges/universities.  Individual participating institutions determine classroom selection for the 
survey and students are then randomly selected.  No identifying information is collected on 
participating students.  This extensive survey consists of 65 questions that are wide ranging 
including demographics and health related questions.  The themes of the questions include 
preventive health (including vaccination history), alcohol, tobacco and drug use, sexual health 
and safety, nutrition and weight management, encounters with violence and personal safety and 
mental wellness (American College Health Association, Who are we?  2012).      
Data/Population 
The obtainable data for use was from fall 2008 to fall 2010.  The data provided a sample 
size of 67,762 women from 253 U.S. higher education institutions.  This survey was found to be 
both valid and reliable by pilot studies from 1998-1999 and comparisons with other national 
survey studies including as the CDC’s National College Health Risk Behavior Survey  
(American College Health Association-National College Health Assessment, Generalizability, 
reliability, and validity analysis, 2012).   
Variables 
The dichotomous dependent variable is HPV vaccination; the NCHA specifically asked 
female participants if they had received the HPV vaccination.  Predictor variables included race, 
age (19-26 years), number of sexual partners, self-classification of obesity, presence of health 
insurance, routine gynecological exam in the past 12 months and influenza vaccination.  Age and 
number of sexual partners’ were continuous variables in the original survey but were changed to 
categorical for the analysis.   
Analysis 
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Descriptive statistics and binary logistic regression was employed in this analysis.  The 
IBM SPSS Statistical version 21 was used for the data analysis. The significance level was p< 
.05.    
Hypotheses 
Due to lack of prodigious research regarding HPV vaccination of college women ages 18-26 
null hypotheses were assumed.   
1. H0: There is no difference in demographic characteristics between women who receive 
the HPV vaccine and those who do not. 
2. H0:  There is no difference in HPV vaccination rates in women who have multiple sexual 
partners and those who do not.   
3. H0: There is no difference in HPV vaccination rates between college women who 
describe themselves as obese and those who did not. 
4. H0: There is no difference in HPV vaccination rates of college women who have 
insurance and those who do not. 
5. H0: There is no difference in HPV vaccination rates in college women who receive yearly 
gynecological exams and those who do not.  
6. H0: There is no difference in HPV vaccination rates among college women who receive 




As identified in Table 1, 78% (52,584) of the population self-identified as White/non-
Hispanic, 6.4% (4,404) Black/non-Hispanic, 6.5% (4,464) Hispanic/Latino, 8.8% (5,966) 
Asian/Pacific Islander, and 0.05% (344) American Indian/Alaskan Native/Native Hawaiian.  The 
average age of the female respondents was 20.5 years old.  Approximately 86% of respondents 
reported they were in college for 4 years or less and 95.5% of respondents were enrolled full 
time in college/university.     
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Overall, 49% of respondents reported receiving the HPV vaccine.  The racial group 
reporting the highest percentage of HPV vaccination was White/non-Hispanic women at 51%.  
Minority women reported lower vaccination rates:  Black/non-Hispanic women (44%), 
Hispanic/Latino women (46%), Asian/Pacific Islanders (40%), and Native American/Alaskan 
Native/Hawaiian native women (49%) (See Figure 1).  There were statistically significant 
differences in vaccination rates between White/non-Hispanic women and minority women 
([X2(4, N=67,762) =327.957, p=.000]).  
 
Table 1    
Characteristics of respondents N=67,762    
   n (%) 
Race    
White/non-Hispanic   52,584 (78.0) 
Black/non-Hispanic   4,404 (6.4) 
Hispanic/Latino   4,464 (6.5) 
Asian/Pacific Islander   5,966 (8.8) 
American Indian/Alaskan Native/Native Hawaiian   344 (0.05) 
Age (years)    
18-20   40,760 (60.0) 
21-23   21,061 (91.1) 
24-26   5,938 (8.8) 
Number of sexual partners in past 12 months    
0   20,974 (31.0) 
1   50,682 (43.4) 
2 or more   7,717 (11.4) 
Did not respond   9,630 (14.2) 
Self-classification of obesity    
No   59,266 (87.5) 
Yes   6,126 (9.0) 
Did not respond   2,370 (3.5) 
Presence of health insurance    
No   3,143 (4.6) 
Yes   64,234 (94.8) 
Did not respond   385 (0.6) 
Routine gynecological exam in past 12 month    
No   30,644 (45.2) 
Yes   37,118 (54.8) 
Influenza vaccination    
No   42,382 (62.5) 
Yes   25,380 (37.5) 
Percentages may not equal 100% due to rounding 
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Respondents receipt of HPV vaccination by race
 
Respondents reported an average of 1.3 sexual partners.  Thirty-one percent of women 
reported that they had zero sexual partners in the past twelve months, 43.4% reported one sexual 
partner, and 11.4% had two or more partners. Furthermore, 9% of women reported that they 
were obese and 4.6% of respondents did not have health insurance at the time of the survey.  The 
survey revealed that 54.8% of respondents reported that they had a gynecological exam in the 
past 12 months and 37.5% of women received the influenza vaccination (see Table 1). 
Binary Regression: 
The results of the non-linear binary logistic regression, which demonstrates statistical 
significance and likelihood of receiving the HPV vaccine in the presence of the independent 
variables, are displayed in Table 2.  Compared to White/non-Hispanic women, Black/non-
Hispanic women in this survey were 28% less likely to receive the HPV vaccination (p=.000).  
Asian/Pacific Islander women were nearly 25% less likely to have received the HPV vaccine 
(p=.000).  Hispanic/Latino women were 8% less likely to receive the HPV vaccination (p=.03).  
There was no statistical significance when Native American/Alaskan Native/Native Hawaiian 
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women were compared to White/non-Hispanic women (p=.704).  As women aged, they were less 
likely to receive the HPV vaccine. Women between the ages of 21-23 were 60% and women 24-
26 years of age were near 75% less likely to have received the vaccine (p=.000) when compared 
to women in the 18-20 age group.   
 Reporting an increase in the number of sexual partners increased the likelihood of 
receiving the HPV vaccine.  Women who reported one sexual partner had a 7% increase in the 
likelihood of HPV vaccination (p=.002) when compared to women who reported no sexual 
partners.  Women with 2 or more sexual partners had a 32% increase in the likelihood of HPV 
vaccination (p=.000).  Women who reported that they were obese had a 15% decrease in the 
likelihood of HPV vaccination when compared to their non-obese counterparts (p=.000). 
Preventive health behaviors tested in the analysis showed that women with health insurance were 
1.8 times more likely to receive the HPV vaccine (p=.000) when compared to women who had 
no health insurance.  Women who underwent a gynecological exam in the past 12 months were 
1.8 times more likely to receive the HPV vaccine than those who did not (p=.000).  The binary 
regression model also demonstrated that women who received an influenza vaccine were more 
than 2.5 times more likely to have received the HPV vaccination compared to those who did not 
(p=.000).  There was concern regarding large sample size effect in this analysis. It was important 
to determine if the large sample size itself caused significance.  It was found that with even a 
large sample the size effect was limited.  Using the odds-ratios and converting to size effect, it 
was found that the magnitude was < 1.48 which does not indicate a size effect.  The pseudo R2 of 
.165 is not prognostic for size effects.  The data analysis rejects the null hypotheses.   
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Table 2:  Odds-Ratios    
  95% Confidence interval 
 Odds-Ratio Upper Lower 
    
Study variables    
Race    
White/non-Hispanic (ref) 1   
Black/non-Hispanic* .719 .667 .776 
Hispanic/Latino*** .921 .856 .990 
Asian/Pacific Islander* .754 .708 .803 
American Indian/Alaskan 
Native/Native Hawaiian 
.952 .741 1.225 
Age     
18-20 years (ref) 1   
21-23 years* .411 .395 .429 
24-26 years* .242 .225 .259 
Number of sexual partners    
0 (ref) 1   
1** 1.072 1.027 1.118 
2 or more* 1.320 1.242 1.401 
Obese    
No (ref) 1   
Yes * .848 .797 .902 
Health insurance status    
No insurance (ref) 1   
Has insurance coverage* 1.885 1.716 2.071 
Gynecological exam status    
Did not receive (ref) 1   
Received* 1.894 1.819 1.973 
Influenza vaccination status    
Did not receive (ref) 1   
Received* 2.683 2.586 2.784 
Ref (denotes reference category) 
   
*P<.000 
   
**p<.01 
   
***p<.05 






In this analysis, Black, Hispanic and Asian college women ages 18-26 all demonstrated 
lower HPV vaccination rates when compared to White women, which is consistent with previous 
research regarding HPV vaccination rates (Bendik, Mayo, and Parker, 2011, Licht, Murphy, 
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Hyland, Fix, Hawk, Mahoney, 2010).  This study also demonstrated that minority women had a 
lower likelihood of receiving the HPV vaccine.  This study supports past research that found 
younger women had higher likelihood of receiving the HPV vaccine; this is most likely due to 
lack of awareness of the 2006 vaccine recommendation (Licht, et al., 2010).   Research 
expanding HPV knowledge and vaccine recommendations for all women 18-26 years of age is 
justifiable.  
An increase in the number of sexual partners was shown to increase the likelihood of 
receiving the HPV vaccine.  These women may have been seeking protection from sexually 
transmitted disease, but there is no way to confirm this postulate. Research specifically 
examining patient expectation(s) of the vaccine should be considered.  It was also found that 
obese women were less likely to report receiving the vaccine which is also in agreement with 
past research (Wee, McCarthy, Davis, & Phillips, 2000).  Increased research dealing with 
barriers to HPV vaccination in obese women is needed to decease their burden of cervical 
cancer.  
Women in this analysis who had health insurance coverage had an increased likelihood of 
receiving the HPV vaccine.  The rates of HPV vaccination should be monitored closely as 
insurance coverage increases in the new US market.  Theoretically, as more women are covered 
by insurance due to the Affordable Care Act (2010), HPV vaccination rates may increase. It is 
important to note that it is now mandated by the Department of Health and Human Services that 
the HPV vaccine be included in health insurance policies (National Cancer Institute, The 
President’s Cancer Panel, 2012).  It would be encouraging if HPV vaccination rates in the catch-
up group increased as insurance coverage rates increased. 
This study also demonstrated that the presence of preventive health behaviors, such as 
receiving a gynecological exam in the past 12 months and receiving the influenza vaccine, 
increased the likelihood of receiving the HPV vaccine.  This research is in agreement with 
preceding studies that showed provider contact increased the likelihood of receiving the vaccine 
(Bendik, et al., 2011, Brewer & Fazekas, 2007, Giambi, Donati, Declich, Salmaso, Degli, Marta, 
& Alibrandi, 2011, Rosenthal, Weiss, & Zimet, 2011). One original aspect of this analysis is that 
only visits to gynecologists were considered.  Specifically exploring gynecological exam rates 
and HPV vaccination rates was not explicitly done in other survey research.  Furthermore, 
research should be expanded to other healthcare providers who deliver sexual health services for 
women (e.g. internists and family practice doctors). Again advocating for increased provider 
visits (i.e. gynecologic/primary care exams) in the female student population could be a window 
of opportunity for student health services to increase HPV education and vaccination.  The 
combination of increasing health insurance rates and health provider visits could be strong 
catalyst for increasing vaccination rates even among women who report that they are obese.  
Bearing in mind that Healthy People 2020 calls for a HPV vaccination rate of 80% in women, 
policy makers and the medical community may decide that strategies to increase the vaccination 
rate in women 18-26 years of age is warranted.   
The greatest strength of this analysis is the large diverse sample size afforded by the 
ACHA-NCHA (N=67,762).  Combining women from 253 educational institutions added to the 
vigor of this analysis.  This large, diverse sample size provided a more inclusive examination of 
barriers to HPV vaccination than past studies that relied on small sample sizes in homogenous 
college populations where only one or two institutions were reflected (Caron, et al., 2009, 
Caskey, et al., 2009, Kahn, et al., 2008, Licht, et al., 2010, Marchand, et al., 2012).  Another 
unique variable included in this analysis was the delivery of the influenza vaccine. Both the 
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influenza and HPV vaccines are voluntary. Exploring variables that may influence individuals to 
seek voluntary vaccinations against infections is warranted.  Promoting voluntary vaccination in 
the US population could be an avenue to reduce infection/disease rates; therefore, potentially 
deceasing future healthcare costs.   
 It is important to note that Pap smear recommendations have recently changed. The past 
recommendation was that females obtain a yearly Pap smear after the initiation of sexual 
intercourse, regardless of age, or at the age of 21.   As of March 2012 the screening guidelines 
for cervical cancer have changed.  These new recommendations are due to the fact that HPV is 
often transient. If a woman in her 20’s is infected with HPV 16 or 18; there is a high likelihood 
that the infection will clear her body within two years.  Cancerous lesions are also extremely rare 
in women under the age of 40. The updated guidelines suggest that women 21-29 receive the Pap 
test every 3 years. It is also recommended that women 30-65 receive the Pap test every 3 years or 
every 5 years if testing for HPV is negative (ACS,2012).   Provider contact for young women 
may decrease if women do not regularly seek gynecological care.  The effect these new 
recommendations have on HPV vaccination rates needs to be monitored.    
 Examination of additional variables that enable or hinder these young women to receive 
the HPV vaccine has merit. Students of different racial backgrounds may experience different 
barriers to HPV vaccination. Therefore, future research regarding individual racial group barriers 
should be explored at greater length. Physicians and other healthcare providers may find that 
understanding the barriers to HPV vaccination among college women could be useful when 
promoting the HPV vaccine.  Student health departments could also benefit from continued 
research, since they are a source of sexual healthcare for college women.  HPV vaccination in 
college women is an under-explored and complex issue, all health promoters would be well 
served by continuous research.   
Limitations exist in this study.  The survey did not directly measure socioeconomic status 
which would have been extremely helpful in comparison with past research.  Similarly the 
survey did not evaluate stigma of receiving the HPV vaccine.  Increasing research dealing with 
the HPV vaccine stigma is necessary.  Limitations regarding self-reporting should be 
acknowledged.  Response bias, the tendency to answer questions a specific way regardless of the 
truth, is a concern when interpreting survey data. This analysis should not be generalized to all 
college age women, since the colleges/universities voluntarily participated in the survey. There 
was also no way to determine if the respondents received the full HPV vaccination series (i.e. 
three injections over a six month period). It can only be assumed that the respondents received at 
least one dose of the vaccine series.  Expanding research to all women in the catch-up group is 
needed; this survey was limited to college students who were easier to isolate. 
 
CONCLUSION 
HPV is the most common sexually transmitted disease in the US.  The long term effect of 
this virus is the possible development of cervical cancer.  The CDC has recommended that 
women up to the age of 26 receive this vaccine, but the vaccine is not widely disseminated in 
women over 18.  Using a large survey of college women, this research provided insight into HPV 
vaccination rate disparities and potential barriers to vaccination. Understanding these disparities 
and barriers are important when formulating strategies to increase HPV vaccination rates to what 
is desired by Healthy People 2020.  Additionally, a goal of The Patient Protection and 
Affordable Care Act (2010) is to decrease health disparities faced by minorities. A greater 
understanding of HPV vaccination barriers in women could aid in approaching this goal.  While 
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this study could not conceivably explore every barrier to HPV vaccination, it did provide insight 
into vaccination disparities and a number of barriers.   
In this analysis of college women, White/non-Hispanic women had a higher HPV 
vaccination rate than minority women.  Health promotion activities that target minority women, 
who are potentially under-vaccinated, could lessen the morbidity and mortality due to cervical 
cancer.  Women who engaged in positive health behaviors, such as receiving a gynecological 
exam and receiving the influenza vaccine, had an increased likelihood of receiving the HPV 
vaccine.  Promoting positive health behaviors, such as gynecological exams, could be a window 
of opportunity to educate women regarding the HPV vaccine. Student health departments and 
other facilities which provide health services to college age women could formulate strategies to 
advocate HPV vaccination.  Increasing provider contact and health insurance coverage could 
potentially be an enormous step in increasing the rate of HPV vaccination in women ages 18-26.  
Health promoters will benefit from continued research regarding barriers to HPV vaccination.  
The health community should maintain a focus on women’s health to afford young women the 
opportunity to receive the HPV vaccine along with other preventative health measures.   
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